(CPRX) Catalyst Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CPRX) Catalyst Pharmaceuticals, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Catalyst Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The content shown on this page is a real preview of the actual report, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
No clear Star asset
By end-2025, Catalyst Pharmaceuticals, Inc. still lacks a clear Star asset because no product shows both high market share and high growth. FIRDAPSE is the mature cash engine, while AGAMREE is still in launch mode, so it has not yet reached the scale needed to dominate a growing market. That leaves Catalyst Pharmaceuticals, Inc. without a fully established Star in the BCG matrix.
AGAMREE early ramp
AGAMREE is a Star candidate in Catalyst Pharmaceuticals, Inc.'s mix: Catalyst gained U.S. rights in 2024, and the drug targets Duchenne muscular dystrophy, a U.S. market of about 15,000 patients versus the much smaller LEMS base.
The ramp is still early, with prescriptions, payer coverage, and access just building, so near-term sales should track uptake, reimbursement wins, and specialist adoption.
If execution holds, AGAMREE can become a larger growth engine than LEMS and support Catalyst Pharmaceuticals, Inc.'s next leg of revenue growth.
DMD market expansion
Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 male births, and U.S. prevalence is roughly 15,000 to 20,000 patients, so long-term treatment demand is real. Catalyst Pharmaceuticals, Inc. is still early in this market, with its AGAMREE exposure only recently scaling after launch, so revenue is still building from a small base. That growth path is why the asset stays under close watch in the BCG Matrix.
Two-brand focus
Catalyst Pharmaceuticals, Inc. runs on two rare-disease brands: FIRDAPSE, its mature cash base, and AGAMREE, its growth driver. That focus keeps execution tight, but it also means the Stars bucket is narrow, with no broad multi-brand balance to offset a slowdown in either product.
FIRDAPSE still anchors the business, while AGAMREE is the main upside case as it scales from a smaller base. So the BCG profile is strong, but concentrated: one stable franchise funds the other’s expansion, instead of a wide portfolio of Star assets.
- Two-brand model drives most commercial value
- FIRDAPSE is the mature revenue base
- AGAMREE is the growth bet
- Concentration limits portfolio breadth
Launch-stage commercial build
Catalyst Pharmaceuticals, Inc. is still in launch-build mode, funding promotion, specialty pharmacy access, and reimbursement support for a rare-disease product. That spend is normal early on, but it also means margin pressure stays visible before the franchise scales.
A true Star needs both strong growth and real share, and Catalyst Pharmaceuticals, Inc. has not shown that mix yet in a way that clearly separates it from a launch-stage build. The signal to watch is whether 2025 to 2026 sales growth starts to outrun launch costs and turns into durable, share-led profit.
- Heavy launch spend is still expected
- Access work supports rare-disease uptake
- Star status needs growth plus share
- Current profile is still early-stage
Catalyst’s Star Still Missing, but AGAMREE Could Change the Story
Stars are still absent for Catalyst Pharmaceuticals, Inc. in 2025-2026. FIRDAPSE remains the cash base, while AGAMREE is the only real Star candidate after Catalyst Pharmaceuticals, Inc. gained U.S. rights in 2024; its Duchenne muscular dystrophy market is about 15,000 to 20,000 U.S. patients, but the launch is still early.
| Asset | 2025-2026 read |
|---|---|
| FIRDAPSE | Mature cash engine |
| AGAMREE | Early Star candidate |
| DMD market | 15,000-20,000 U.S. patients |
What is included in the product
Detailed Word Document
Catalyst’s BCG Matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Clean BCG matrix view for Catalyst Pharmaceuticals to quickly spot growth and cash-cow segments.
Reference Sources
Catalyst Pharmaceuticals, Inc. reference sources provide a credible, traceable trail that speeds due diligence and strengthens decisions.
Cash Cows
FIRDAPSE adult LEMS
FIRDAPSE is Catalyst Pharmaceuticals, Inc.'s flagship amifampridine brand and the clearest cash cow in the portfolio. In 2024, it generated about $157 million in net product sales, supported by its use in ultra-rare Lambert-Eaton myasthenic syndrome. The niche patient base and chronic dosing help keep demand steady and margins high.
FIRDAPSE pediatric label
FIRDAPSE’s pediatric LEMS label expands use beyond adults, widening the treated pool and helping protect Catalyst Pharmaceuticals, Inc.’s installed base. That matters in a rare disease market, where each added patient can extend franchise longevity. The broader label also supports more durable U.S. revenue per patient as the brand reaches younger long-term users.
Amifampridine franchise
The amifampridine franchise remains Catalyst Pharmaceuticals, Inc.'s legacy cash cow: a niche orphan therapy for Lambert-Eaton myasthenic syndrome with repeat prescriptions and high pricing power. In 2025, that steady, narrow patient base continued to support strong cash generation, while mature orphan-drug economics kept gross margins near 80%. The core molecule still anchors most of the franchise's value.
Specialist neuromuscular base
Catalyst Pharmaceuticals, Inc. sells into a narrow set of neuromuscular specialists, not a broad primary-care base. That keeps call plans, education, and promotion lean, which fits the Cash Cow profile; its rare-disease markets are also small and concentrated, with FIRDAPSE addressing a low-thousands U.S. patient pool.
- Focused specialist selling lowers CAC.
- Rare-disease demand is concentrated.
- Low commercial complexity supports margins.
Main revenue engine
FIRDAPSE remains Catalyst Pharmaceuticals, Inc.’s main revenue engine and the clearest Cash Cow in its BCG mix. In 2024, Catalyst reported total revenue of about $528 million, with FIRDAPSE still driving the bulk of marketed-product cash flow while the company funded launches for newer assets like AGAMREE and FYCOMPA.
This fits the Cash Cow label because FIRDAPSE is a mature, established brand that keeps generating operating cash with limited heavy launch spend. That cash helps Catalyst pay for commercialization, R&D, and portfolio expansion without relying as much on outside capital.
- Largest marketed asset
- Supports core operating cash
- Funds newer product launches
- Strong Cash Cow fit
FIRDAPSE Powers Catalyst’s Cash Flow Engine
FIRDAPSE is Catalyst Pharmaceuticals, Inc.'s clear Cash Cow: in 2024 it generated about $157 million in net product sales and kept recurring demand in ultra-rare LEMS. Its 2025 pediatric label broadens the treated pool, while the mature orphan-drug model supports high margins and steady cash flow.
| Cash Cow | 2024 Net Sales | Role |
|---|---|---|
| FIRDAPSE | $157M | Core cash engine |
Get Your Copy
Catalyst Pharmaceuticals, Inc. Reference Sources
The Catalyst Pharmaceuticals, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the complete, professionally formatted report. It’s ready to download, edit, print, and share right away. What you preview is what you get.
Dogs
RUZURGI legacy brand
RUZURGI was Catalyst Pharmaceuticals, Inc.'s pediatric amifampridine brand, but it became redundant once FIRDAPSE won the broader Lambert-Eaton myasthenic syndrome label. With 2 overlapping amifampridine brands and little stand-alone growth, RUZURGI fits the Dog bucket in a BCG Matrix. It is a legacy rare-disease product with low strategic value now.
Endo Sabril agreement
Catalyst Pharmaceuticals, Inc. "s generic Sabril tablet agreement fits a non-core, mature epilepsy-generic niche with limited strategic upside. The U.S. epilepsy market is crowded, and generic antiseizure drugs typically face steep price erosion and thin margins, so share gains are hard to sustain. That makes the asset look closer to a "dog" than a growth driver.
Legacy licensing deals
Older licensing deals, including the BioMarin arrangement noted in Catalyst Pharmaceuticals, Inc. disclosures, are low-impact legacy assets, not the company’s main growth engine. Catalyst’s 2025 story is still driven by core rare-disease sales, while these older contracts sit in the Dogs bucket because they add little to revenue growth or strategy.
Duplicative amifampridine assets
Catalyst Pharmaceuticals, Inc. has built amifampridine around a very small orphan market, so a second overlapping brand adds little new demand. When one branded path already covers the core patient base, the extra asset mostly splits sales and raises support cost, which fits a Dog profile.
- Small market, low growth
- Overlap cuts incremental value
- Commercial defense is weak
Non-core small programs
Catalyst Pharmaceuticals, Inc.'s non-core small programs fit the Dog profile: small, inactive, and unlikely to reach a late-stage readout. The Company's value is tied to approved products, while legacy pipeline items do not show a clear path to meaningful share or cash flow. In 2024, Catalyst generated over $400 million in net product sales, so these programs are tiny by comparison.
- Low sales potential
- No clear late-stage path
- Management time drain
- Weak return outlook
Catalyst’s Legacy “Dogs” Are Small, Low-Growth Drags on the Core Story
Dogs in Catalyst Pharmaceuticals, Inc. are legacy, low-growth assets like RUZURGI, the generic Sabril deal, and older licensing items. They add little to the 2025 core rare-disease engine, while overlap and weak pricing limit upside. Catalyst Pharmaceuticals, Inc. still drew over $400 million in net product sales in 2024, so these assets are small by comparison.
| Dog asset | Why it fits |
|---|---|
| RUZURGI | Overlap, no growth |
| Generic Sabril | Thin margins, crowded |
Question Marks
AGAMREE DMD launch
AGAMREE is Catalyst Pharmaceuticals, Inc.’s newest growth asset: it launched in 2024 for Duchenne muscular dystrophy and has a small base, with U.S. net product sales still early versus Catalyst Pharmaceuticals, Inc.’s established rare-disease drugs.
That makes it a classic Question Mark in the BCG Matrix: the market is attractive, but AGAMREE still needs share gains and broader uptake to prove scale.
Its upside is real, but so is the execution risk, since the product must convert launch momentum into durable prescription growth.
MuSK MG study
Catalyst Pharmaceuticals, Inc.’s FIRDAPSE has been explored in MuSK antibody positive myasthenia gravis, a much larger pool than LEMS if results hold. LEMS is rare, with only a few thousand patients in the U.S., while generalized myasthenia gravis affects tens of thousands, so the upside is bigger. But MuSK MG is still an unproven expansion play, so it belongs in the Question Marks quadrant.
SMA type 3 study
Catalyst Pharmaceuticals, Inc.'s SMA type 3 work on FIRDAPSE is a true question mark: it is a possible label expansion, not a current revenue driver. It has no commercial impact unless clinical data and FDA review support the new use. Until then, value stays tied to the core LEMS franchise, not SMA3.
HNPP study
Hereditary neuropathy with liability to pressure palsies is an exploratory FIRDAPSE target, but it is still pre-commercial. HNPP is ultra-rare, with prevalence often cited around 1 in 50,000, so the revenue pool is tiny and clinical validation still matters more than near-term sales.
This makes HNPP a classic Question Mark in Catalyst Pharmaceuticals, Inc.'s BCG matrix: high uncertainty, low current cash generation, and a long path to scale.
- Ultra-rare market
- Pre-commercial program
- High execution risk
New indication bets
Catalyst Pharmaceuticals, Inc. has kept its growth bets tight: it leans on indication expansion, not a broad R and D platform. That makes new uses for existing assets the main upside case, but until a label win lands and sales ramp, these programs still sit in the Question Mark quadrant.
- Growth depends on approval, then uptake.
- Pipeline is narrow, not platform-based.
- Unproven indications stay high-risk, high-reward.
Catalyst’s Question Marks: High Upside, Unproven Growth
Question Marks at Catalyst Pharmaceuticals, Inc. are the newer or unproven growth bets: AGAMREE launched in 2024, FIRDAPSE expansion in MuSK MG, SMA type 3, and HNPP. They offer bigger upside than LEMS, but each still needs approval, uptake, or stronger data to turn into sales.
| Program | Status | Market signal |
|---|---|---|
| AGAMREE | Launch phase | Small base |
| MuSK MG | Unproven expansion | Tens of thousands |
| HNPP | Pre-commercial | About 1 in 50,000 |
That is why they sit in the Question Mark quadrant: high potential, but no clear proof yet that Catalyst Pharmaceuticals, Inc. can scale them fast.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.